Keryx Biopharmaceuticals, Inc. at Stifel’s 2017 Healthcare Conference (Replay)
11/14/17 at 3:30 p.m. ET
Keryx Biopharmaceuticals, Inc. at Jefferies’ 2017 Global Healthcare Conference (Replay)
11/16/17 at 8:40 a.m. GMT
Keryx Biopharmaceuticals, Inc. fireside chat at 29th Annual Piper Jaffray Healthcare Conference (Live)
11/28/17 at 2:00 p.m. ET
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine. Patients have been and continue to be at the center of our nearly 20-year corporate history.
Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 200 employees across Boston and our field teams.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.